Ionis Pharmaceuticals (NASDAQ:IONS) Releases Earnings Results, Beats Estimates By $0.46 EPS

Ionis Pharmaceuticals (NASDAQ:IONS) posted its earnings results on Wednesday. The company reported ($0.66) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.46, RTT News reports. The firm had revenue of $227.00 million during the quarter, compared to the consensus estimate of $140.97 million. Ionis Pharmaceuticals had a negative return on equity of 88.98% and a negative net margin of 44.58%. The company’s quarterly revenue was down 30.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.12 EPS. Ionis Pharmaceuticals updated its FY 2025 guidance to EPS.

Ionis Pharmaceuticals Stock Down 1.3 %

NASDAQ IONS traded down $0.42 during trading on Wednesday, hitting $31.54. The company’s stock had a trading volume of 1,966,937 shares, compared to its average volume of 1,596,154. The company has a debt-to-equity ratio of 1.86, a current ratio of 8.91 and a quick ratio of 8.82. The company has a market cap of $4.98 billion, a PE ratio of -12.96 and a beta of 0.34. The business’s 50 day simple moving average is $33.94 and its 200-day simple moving average is $38.55. Ionis Pharmaceuticals has a fifty-two week low of $30.23 and a fifty-two week high of $52.34.

Wall Street Analyst Weigh In

Several analysts recently weighed in on IONS shares. Piper Sandler decreased their price target on Ionis Pharmaceuticals from $65.00 to $62.00 and set an “overweight” rating on the stock in a report on Thursday, November 14th. StockNews.com lowered Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. William Blair restated an “outperform” rating on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Royal Bank of Canada restated an “outperform” rating and set a $70.00 price target on shares of Ionis Pharmaceuticals in a report on Wednesday, January 15th. Finally, Needham & Company LLC restated a “buy” rating and set a $60.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, December 20th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $60.65.

Insiders Place Their Bets

In other Ionis Pharmaceuticals news, CFO Elizabeth L. Hougen sold 8,870 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.81, for a total value of $291,024.70. Following the completion of the sale, the chief financial officer now owns 107,885 shares of the company’s stock, valued at approximately $3,539,706.85. This trade represents a 7.60 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brett P. Monia sold 33,445 shares of the firm’s stock in a transaction dated Thursday, January 16th. The stock was sold at an average price of $32.63, for a total value of $1,091,310.35. Following the completion of the sale, the chief executive officer now directly owns 207,396 shares of the company’s stock, valued at approximately $6,767,331.48. This represents a 13.89 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 110,609 shares of company stock valued at $3,564,867. 2.71% of the stock is currently owned by corporate insiders.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.